Search Result

Results for "

OVCaR-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amyloid-β (2) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (10) Bacterial (1) Caspase (1) CDK (4) COX (2) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Metabolite (1) Ephrin Receptor (1) Epigenetic Reader Domain (1) Ferroptosis (1) Fungal (1) Histone Acetyltransferase (1) Integrin (1) Kinesin (11) MDM-2/p53 (1) Microtubule/Tubulin (10) mTOR (2) NO Synthase (2) p38 MAPK (2) Parasite (1) PARP (1) PI3K (2) Polo-like Kinase (PLK) (1) PROTACs (1) Raf (1) Ras (1) Reactive Oxygen Species (3) ROS Kinase (1) Ser/Thr Protease (1) Toll-like Receptor (TLR) (2) Wee1 (2)
By Research Areas:	Cancer (38) Infection (1) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Akt (2)

Amyloid-β (2)

Antibody-Drug Conjugates (ADCs) (2)

Apoptosis (10)

Bacterial (1)

Caspase (1)

CDK (4)

COX (2)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Drug Metabolite (1)

Ephrin Receptor (1)

Epigenetic Reader Domain (1)

Ferroptosis (1)

Fungal (1)

Histone Acetyltransferase (1)

Integrin (1)

Kinesin (11)

MDM-2/p53 (1)

Microtubule/Tubulin (10)

mTOR (2)

NO Synthase (2)

p38 MAPK (2)

Parasite (1)

PARP (1)

PI3K (2)

Polo-like Kinase (PLK) (1)

PROTACs (1)

Raf (1)

Ras (1)

Reactive Oxygen Species (3)

ROS Kinase (1)

Ser/Thr Protease (1)

Toll-like Receptor (TLR) (2)

Wee1 (2)

By Research Areas:

Cancer (38)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N3558

Ceanothic acid Emmolic acid	Others	Cancer
Ceanothic acid (Emmolic acid) is a ring-A homologue of betulinic acid. Ceanothic acid inhibits OVCAR-3, HeLa, and FS-5 cells with the cell survival of 68%, 65%, and 81%, respectively .

HY-P5098

E(c(RGDfK))2	Integrin	Cancer
E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .

HY-N0022

Isoacteoside 3 Publications Verification Isoverbascoside	Apoptosis Reactive Oxygen Species Akt mTOR PI3K NO Synthase COX p38 MAPK Toll-like Receptor (TLR) Amyloid-β	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside regulates the *AKT/PI3K/m-TOR/NF-κB* signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities ^[3] .

HY-145389

SZ-015268	CDK	Cancer
SZ-015268 is a CDK7 inhibitor with an IC₅₀ of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC₅₀s of 33, 80.56, 12.53, and 61.55 nM, respectively .

HY-164978

KIF18A-IN-14	Kinesin	Cancer
KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC₅₀s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-164979

KIF18A-IN-15	Kinesin	Cancer
KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, with IC₅₀s of 0.01-0.1 μM, respectively. EX36-A and EX36-B inhibit OVCAR-3 cells viability with IC₅₀s of 0.01-0.1 μM and 0-0.01 μM, respectively. KIF18A-IN-15 can be used in tumor (e.g. colon, breast, lung) studies .

HY-N7760

Neosalvianen	Others	Others
Neosalvianen is a N-containing compound that shows cytotoxic activities against the HeLa, HepG2, and OVCAR-3 cell lines, with IC₅₀ of 63.9 µM, 59.2 µM, and 74.6 µM, respectively .

HY-N10544

δ-Cadinene (+)-δ-Cadinene	Bacterial Parasite Fungal Apoptosis	Infection Cancer
δ-Cadinene ((+)-δ-Cadinene) is a sesquiterpene in essential oils. δ-Cadinene shows antiproliferative and pro-apoptotic effects on human ovary cancer (OVCAR-3) cells. δ-Cadinene has trichomonacidal, antimicrobial, antifungal and anticancer properties .

HY-N10268

3-Hydroxyterphenyllin NSC 299113	Apoptosis	Cancer
3-Hydroxyterphenyllin is a metabolite of Aspergillus candidus.3-Hydroxyterphenyllin suppresses proliferation and causes cytotoxicity against A2780/CP70 and OVCAR-3 cells. 3-Hydroxyterphenyllin induces S phase arrest and apoptosis. 3-Hydroxyterphenyllin has the potential for the research of ovarian cancer .

HY-155966

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-167876

PQR514	Others	Cancer
PQR514 is a potent PI3K inhibitor with anticancer activity. PQR514 is able to inhibit cancer cell proliferation. PQR514 showed significant antitumor activity in the OVCAR-3 xenograft model, with the required concentration being approximately one-eighth that of PQR309. PQR514 has good pharmacokinetic properties and minimal brain penetration, making it an optimized candidate compound for inhibiting systemic tumors .

HY-N0022R

Isoacteoside (Standard)	Toll-like Receptor (TLR) Amyloid-β Apoptosis Reactive Oxygen Species Akt mTOR PI3K NO Synthase COX p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Isoacteoside (Standard) is the analytical standard of Isoacteoside. This product is intended for research and analytical applications. Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside Standard regulates the *AKT/PI3K/m-TOR/NF-κB* signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside Standard exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities .

HY-169476

Pyrrolidine linoleamide	Drug Derivative	Cancer
Pyrrolidine linoleamide is a derivative of linoleic acid amide with anticancer activity. Pyrrolidine linoleamide exhibits antiproliferative activity against a range of cancer cell lines, with IC₅₀ values of 12.0, 27.5, 7.7, 21.9, 36.6, 32.6, and 33.9 μg/mL against U251, MCF-7, NCI-ADR/RES, 786-0, NCI-H460, PC-3, and OVCAR-3 cell lines, respectively .

HY-158683

KIF18A-IN-11	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer .

HY-168057

PROTAC CDK2 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀ of 100-500 nM .

HY-162531

KIF18A-IN-9	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-9 (Compound 1) is a potent KIF18A inhibitor, with an IC₅₀ value of 3.8 nM. KIF18A-IN-9 has anticancer activity, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .

HY-162532

KIF18A-IN-10	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC₅₀ value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .

HY-168180

WEE1-IN-11	Wee1	Cancer
WEE1-IN-11 (Compound 13) is a potent CDK2 inhibitor with an IC₅₀ of 2.0 nM. WEE1-IN-11 inhibits NCI–H446, A427, OVCAR3, C33A,and WiDr cells with IC₅₀s of 93.9, 34.5, 86.7, 23.1, and 85 nM, respectively .

HY-170517

PKMYT1-IN-8	Wee1 Ephrin Receptor	Cancer
PKMYT1-IN-8 (Compound 137) is the inhibitor for PKMYT1 with an IC₅₀ of 9 nM. PKMYT1-IN-8 inhibits *EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2with IC₅₀s of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. PKMYT1-IN-8 inhibits the proliferation of cancer cell OVCAR3* with GI₅₀ of 2.02 μM .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, *CDK6/D3* and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-N10922

(3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone	Others	Cancer
(3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3), a Palmitate, can be isolated from the root tissue of Salvia miltiorrhiza. (3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3) shows anti-cancer activity against human cancer cell lines with DC₅₀s of 25.5 μg/mL (HeLa), 37.5 μg/mL (HepG2), 30.2 μg/mL (OVCAR-3), respectively .

HY-132840

Sovilnesib AMG 650	Kinesin Microtubule/Tubulin	Cancer
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC₅₀ value of 0.071 μM. Sovilnesib can be used for the research of cancer .

HY-N1639

1-Decarboxy-3-oxo-ceanothic acid DOCA	Apoptosis DNA/RNA Synthesis	Cancer
1-Decarboxy-3-oxo-ceanothic acid is an anticancer agent. 1-Decarboxy-3-oxo-ceanothic acid inhibits DNA synthesis. 1-Decarboxy-3-oxo-ceanothic acid induces Apoptosis .

HY-145803

KIF18A-IN-3	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-3 is a potent KIF18A inhibitor (IC₅₀=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer .

HY-145802

KIF18A-IN-2	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-2 is a potent KIF18A inhibitor (IC₅₀=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer .

HY-151879

Tubulin inhibitor 30	Microtubule/Tubulin Ferroptosis	Cancer
Tubulin inhibitor 30 (Compound 15) is a tubulin assembly inhibitor with an IC₅₀ of 0.52 μM. Tubulin inhibitor 30 can induce ferroptosis .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99593A

Sofituzumab vedotin (solution) DMUC5754A (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .

HY-158757

KIF18A-IN-12	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-12 (compound 9) is a KIF18A inhibitor, with an IC₅₀ value of 45.54 nM. KIF18A-IN-12 can be used in cancer research .

HY-145827

KIF18A-IN-4	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC₅₀=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .

HY-104000

BAY-320	Ser/Thr Protease	Cancer
BAY-320 is a selective and ATP-competitive Bub1 inhibitor that inhibits the kinase activity of Bub1 with an IC₅₀ of 680 nM. BAY-320 inhibits endogenous Bub1-mediated Sgo1 localization. BAY-320 affects cellular mitotic chromosome arrangement and spindle assembly. BAY-320 inhibits cell proliferation. BAY-320 can be used in the study of cancer .

HY-129932

Pyrrolidine ricinoleamide	Others	Cancer
Pyrrolidine ricinoleamide ((R)-5d) is a fatty acid amide that exhibits effective antiproliferative activity against a series of cancer cells, including human glioma U251 cells. Pyrrolidine ricinoleamide can be used in cancer research .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a PARP-1 inhibitor (IC₅₀ = 19.24 nM for PARP-1 and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-N3446

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53	Cancer
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .

HY-162937

KIF18A-IN-13	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer .

HY-12300A

Ocifisertib hydrochloride CFI-400945 hydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Ocifisertib hydrochloride (CFI-400945 hydrochloride) is the hydrochloride salt form of Ocifisertib (HY-12300). Ocifisertib hydrochloride is an orally active PLK4 inhibitor with a K_i and an IC₅₀ of 0.26 nM and 2.8 nM. Ocifisertib hydrochloride inhibits growth of various cancer cells, arrests cell cycles at G2/M phase, and induces apoptosis. Ocifisertib hydrochloride exhibits antitumor efficacy in mouse model .

HY-109583

4-Oxofenretinide 4-Oxo-4-HPR	Apoptosis Reactive Oxygen Species Drug Metabolite	Cancer
4-Oxofenretinide (4-Oxo-4-HPR) is a metabolite of Fenretinide (HY-15373). 4-Oxofenretinide induces cell growth inhibition in ovarian, breast, and neuroblastoma tumor cell lines. 4-Oxofenretinide causes a marked accumulation of cells in G2-M. 4-Oxofenretinide induces cancer cell apoptosis through caspase-9 .

Cat. No.	Product Name	Target	Research Area